G1 Therapeutics, Inc. is a commercial-stage oncology biopharmaceutical company that aims to improve the lives of individuals impacted by cancer through next-generation therapies. The company’s first commercial product is COSELA® (trilaciclib), and they are currently evaluating therapies in combination with cytotoxic therapies and/or immunotherapy for conditions with high unmet needs, such as triple-negative breast cancer and extensive stage small cell lung cancer.
On May 1, 2024, G1 Therapeutics will be hosting a webcast and conference call to provide a financial and corporate update for the first quarter of 2024. The event will begin at 8:30 a.m. ET and can be accessed by following the provided link on the company’s website. It is recommended to join the event 10 minutes prior to the start time. A live and archived webcast will also be available on the Events & Presentations page of the company’s website for those who are unable to attend the live event.
Individuals interested in learning more about G1 Therapeutics can visit their website at http://www.g1therapeutics.com and follow them on social media platforms like X (formerly known as Twitter) @G1Therapeutics and LinkedIn. For further information or inquiries, individuals can contact G1 Therapeutics’ Communications Officer and Vice President of Investor Relations and Corporate Communications, Will Roberts, at (919) 907-1944 or via email at wroberts@g1therapeutics.com. Trademarks owned by G1 Therapeutics, Inc. include G1 Therapeutics®, COSELA®, and their respective logos.